MUNICH, Germany, Nov. 17, 2010 (GLOBE NEWSWIRE) -- Immudyne, Inc. (Pink Sheets:IMMD) is pleased to announce that Sven Rohmann, MD, PhD presented clinical data on Immudyne’s ultra pure beta glucan produced from yeast through a proprietary patented process, in both orally and topically administered forms.
